Bio-Key International Signals Turn Toward Profitability

Bio-Key International ((BKYI)) has held its Q1 earnings call. Read on for the main highlights of the call.

Bio-Key International’s latest earnings call struck an optimistic tone, as management showcased strong top-line growth, expanding high-margin software licenses and sharply reduced losses while acknowledging listing risks and cash pressures. Executives painted a picture of a business turning the corner toward profitability, with global partnerships and a scalable, recurring model offsetting concerns around NASDAQ suspension and regulatory headwinds.

Revenue Growth

Bio-Key reported Q1 2026 revenue of $2.1 million, up 34% from $1.6 million a year earlier, signaling renewed momentum across its product portfolio. Management emphasized that this growth reflects both new customer wins and expansion within existing accounts, suggesting a healthier demand backdrop than in prior periods.

License Fee Expansion

License fees rose 24% year over year to $1.4 million, underscoring the importance of software in the company’s strategy. A key driver was a one‑year renewal from a long‑time banking customer that serves about 30 million clients, highlighting Bio-Key’s ability to retain large enterprise relationships.

Hardware Revenue Surge

Hardware revenue more than doubled to roughly $531,000, supported by increased demand from customers including a foreign Defense Ministry. The company also monetized previously fully reserved inventory, adding around $100,000 in sales and demonstrating an opportunistic use of balance sheet assets.

Improved Gross Profit and Strong Margins

Gross profit grew about 33% year over year, with margins holding at a robust 82%, in line with prior periods. Management credited the mix shift toward higher‑margin licenses and the benefit from selling reserved hardware inventory, reinforcing the underlying profitability of the core software business.

Substantial Net Loss Improvement

Net loss shrank dramatically to $165,036 in Q1 2026 from $736,545 a year earlier, cutting the per‑share loss to $0.15 from $1.57. While the company is not yet profitable, this roughly 77.6% reduction in loss suggests operating leverage is beginning to show through the income statement.

Solid Balance Sheet and Liquidity

At March 31, 2026, book value stood at $7.6 million, or about $7.04 per share, with current assets near $4.5 million. Cash and equivalents totaled around $2.2 million and accounts receivable $1.6 million, giving Bio-Key a modest liquidity cushion as it pursues growth and navigates listing uncertainties.

Partnerships and Distribution Expansion

Management highlighted a strategic partnership with DLT Solutions, the public sector arm of TD Synnex, to integrate PortalGuard IAM and Passkey:YOU into U.S. government procurement channels. The company also expanded its partner footprint in EMEA, India and Vietnam, positioning its biometric and IAM offerings for broader global adoption.

Recurring and Channel-Driven Model

Bio-Key stressed that its business is predominantly subscription-based, creating recurring revenue visibility. Around half of new domestic deals come through partners and all international sales flow through channel relationships, a structure the company believes can scale efficiently without heavy direct sales investment.

Operational Momentum and Outlook

The pipeline is said to be strengthening, with management citing larger deal sizes and more advanced opportunities. Executives expressed confidence in scaling to multi‑million‑dollar quarterly revenues and suggested that the operational trajectory supports near‑term profitability goals.

Corporate Governance and Reporting Progress

The company aims to file its 2025 Form 10‑K this week and quickly follow with the Q1 10‑Q, bringing SEC reporting current. Management noted that an independent review of Q1 results remains pending, leaving open the possibility of adjustments but signaling a clearer path to compliance.

NASDAQ Suspension and Listing Risk

Bio-Key’s shares were recently suspended from NASDAQ and now trade on the OTC market, a setback that management acknowledged as a near‑term overhang. While an appeal hearing is scheduled and advisers are optimistic, the outcome and timing of any relisting remain uncertain for investors.

Delinquent Filings and Investor Noise

The company conceded that past delinquent SEC filings contributed directly to its listing problems and broader investor skepticism. By prioritizing the completion of overdue reports, management hopes to reduce this noise and restore credibility with both regulators and the market.

Cash Decline and Residual Losses

Cash slipped from roughly $2.7 million at year-end to about $2.3 million at quarter’s close, a decline the company linked to timing of collections and shipments. Despite the sharper loss reduction, Bio-Key still operates at a quarterly deficit, underscoring the need to execute on its profitability plan.

Lumpy Hardware and One-Time Effects

Management cautioned that hardware revenue is inherently uneven and partly benefited from non-recurring inventory sales this quarter. Investors were reminded that such one‑time contributions may not repeat, making sustained growth in licenses and recurring contracts critical to the long‑term story.

U.S. Regulatory and Adoption Headwinds

In the domestic market, privacy concerns and regulatory scrutiny continue to slow biometric adoption compared with EMEA and other regions. Bio-Key indicated it is leaning more heavily on international opportunities and partner channels where regulatory regimes and customer openness are more favorable.

Relisting Costs and Legal Expenses

The company acknowledged incremental legal and advisory costs tied to its NASDAQ appeal, adding another layer of near‑term expense. Management, however, believes these costs will not materially disrupt operations and views them as necessary steps to restore an exchange listing.

Forward-Looking Guidance

Looking ahead, Bio-Key guided to continued momentum, projecting first-half revenue around $5 million and expecting to reach profitability and positive cash flow in Q2. The company plans to maintain gross margins near the low‑80% range, keep operating expenses roughly flat, and continue scaling through partners off a post‑reverse‑split share count of about 1.1 million.

Bio-Key’s earnings call portrayed a company balancing clear operational gains with non-trivial listing and regulatory risks, yet tilting firmly toward improvement. For investors, the key takeaway is whether the strengthening recurring revenue base and partner-driven growth can carry the firm to sustainable profitability before market and compliance challenges sap its current momentum.